Examkin

Question

Difficulty: HardMonitoring and Treatment Evaluation

A 68-year-old man is evaluated in the cardiology clinic. He has a history of rheumatic heart disease status post mechanical mitral valve replacement four years ago. He is maintained on warfarin, with a consistently stable INR between 2.5 and 3.5 over the past year. Today, his INR is 2.8. During the visit, the patient reports a 3-week history of episodic palpitations. An electrocardiogram obtained in the clinic confirms new-onset atrial fibrillation. To facilitate rhythm control, the cardiologist decides to initiate oral amiodarone. The patient's other daily medications include lisinopril and atorvastatin. Physical examination is unremarkable. Which of the following is the most appropriate next step in the management of this patient's pharmacotherapy?

  1. Reduce the weekly warfarin dose by 25% to 50% and recheck the INR in 1 to 2 weeksAnswer
  2. B
    Maintain the current warfarin dose and recheck the INR in 1 week
  3. C
    Discontinue warfarin and initiate apixaban
  4. D
    Hold the next two doses of warfarin, resume at a 30% reduced dose, and recheck the INR in 2 weeks
  5. E
    Obtain a transesophageal echocardiogram before adjusting the anticoagulation regimen

Answer

The most appropriate next step is to preemptively reduce the weekly warfarin dose by 25% to 50% and closely monitor the INR in 1 to 2 weeks.
The most appropriate next step in monitoring and treatment evaluation for this patient is to preemptively reduce the weekly warfarin dose by 25% to 50% and recheck the INR in 1 to 2 weeks. Amiodarone is a potent inhibitor of multiple cytochrome P450 enzymes, most notably CYP2C9. Warfarin exists as a racemic mixture, and its more pharmacologically active S-enantiomer is metabolized almost entirely by CYP2C9. When amiodarone is added to a stable warfarin regimen, it reliably decreases warfarin clearance, leading to elevated serum concentrations and a supratherapeutic INR. To prevent severe bleeding complications, clinical guidelines mandate an empiric reduction of the warfarin dose by 25% to 50% at the time amiodarone is initiated, followed by close laboratory monitoring as the new steady-state is achieved.

Step-by-Step Solution

1
Identify the patient's baseline status.
The patient has a mechanical mitral valve and is optimally anticoagulated with warfarin (INR 2.8, target 2.5-3.5).
Establishing the baseline helps determine if the current therapy is effective and guides the urgency of interventions.
2
Analyze the pharmacokinetic impact of the new medication.
Initiation of amiodarone will cause potent inhibition of CYP2C9.
CYP2C9 is the primary enzyme responsible for metabolizing the highly active S-enantiomer of warfarin.
3
Determine the clinical consequence of the drug interaction.
Without intervention, warfarin clearance will decrease, leading to an accumulation of the drug, a supratherapeutic INR, and a high risk of spontaneous hemorrhage.
Anticipating the interaction is necessary for preventive patient management.
4
Select the guideline-concordant monitoring and treatment adjustment.
Empirically reduce the maintenance warfarin dose by 25% to 50% upon starting amiodarone, followed by an INR check in 1 to 2 weeks.
This preemptive strategy safely maintains the INR within the therapeutic window during the transition phase.

Key Concept

When amiodarone is initiated in a patient stabilized on warfarin, the warfarin dose must be preemptively reduced by 25% to 50% due to amiodarone's potent inhibition of CYP2C9, which significantly decreases warfarin clearance.
Estimated Time:1m 15s
Rate this question

Topics

Monitoring and Treatment Evaluation

More questions from this topic